Alerid Syrup 60Ml

COMPOSITION

Each 5 ml contains Cetirizine Hydrochloride IP 5mg. Flavored Syrup base q.s. Excipients with known effects methyl hydroxybenzoate, propyl hydroxybenzoate and sorbitol. 

INDICATIONS

In adults and children 2 years and above: Cetirizine is indicated for relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis. Cetirizine is indicated for tie relief of symptoms of chronic idiopathic urticaria. 

CONTRAINDICATION

Hypersensitivity to active substance, to any of the excipients, to hydroxyzine or to any piperazine derivatives. Patients with severe renal impairment at less than 10 ml/min creatinine clearance. 

WARNINGS & PRECAUTIONS

At therapeutic doses, no clinically significant interactions have been demonstrated with alcohol (for a blood alcohol level of 0.5 g/L). Nevertheless, precaution is recommended if alcohol is taken concomitantly. Caution should be taken in patients with predisposition factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as cetirizine may increase the risk of urinary retention. Caution in epileptic patients and patients at risk of convulsions is recommended. This medicinal product contains methyl- and propyl- par hydroxybenzoates. It may cause allergic reactions (possibly delayed). This medicinal product contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take-this medicine. Allergy skin tests are inhibited by antihistamines and a Wash-out period (Of 3 days) is required before performing them. 

DRUG INTERACTIONS

Due to the pharmacokinetic. pharmacodynamic and tolerance profile of cetirizine, no interactions are expected with this antihistamine. Actually, neither pharmacodynamic nor significant pharmacokinetic interaction was reported in drug-drug interactions studies performed. notably with pseudoephedrine or theophylline (400 mg/day). The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased.

UNDESIRABLE EFFECTS

Clinical studies have shown that cetirizine at the recommended dosage has minor undesirable effects on the CNS, including somnolence, fatigue. dizziness and headache. In some cases, paradoxical CNS stimulation has been reported. Although cetirizine is a selective antagonist of peripheral H1-receptors and is relatively free of anticholinergic activity, isolated cases of micturition difficulty, eye accommodation disorders and dry mouth have been reported. Instances of abnormal hepatic function with elevated hepatic enzymes accompanied by elevated bilirubin have been reported. Mostly this resolves upon discontinuation of the treatment with cetirizine dihydrochloride.

OVERDOSE

Symptoms: Symptoms observed after an overdose of cetirizine are mainly associated with CNS effects or with effects that could suggest an anticholinergic effect. Adverse events reported after an intake of at least 5 times the recommended daily dose is: confusion, diarrhea, dizziness, fatigue, headache, malaise, mydriasis. pruritus, restlessness. sedation. somnolence, stupor. tachycardia. tremor, and urinary retention. Management: There is no known specific antidote to cetirizine. Should overdose occur, symptomatic or supportive treatment is recommended. Gastric lavage should be considered following ingestion of a short occurrence. Cetirizine is not effectively removed by dialysis.

CIPLA LTD